CIRM Funded Clinical Trials

Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors

Disease Area:

Blood Cancer, Solid Tumors

Investigator:

Professor Irving L Weissman MD

Institution:

Stanford University

CIRM Grant:

DR3-06965 (Closed)

Award Value:

$6,505,568.00

Trial Sponsor:

Stanford University

Trial Stage:

Phase 1

Trial Status:

Completed

Targeted Enrollment:

88

ClinicalTrials.gov ID:

NCT02216409

Details:

A team at Stanford University is using a molecule known as an antibody to target cancer stem cells. This antibody can recognize and bind to CD47, a protein the cancer stem cells carry on their cell surface. The cancer cells use that protein to evade the component of our immune system that routinely destroys tumors. By disabling this protein with the CD47 targeting antibody, the team hopes to empower the body’s own immune system to attack and destroy the cancer stem cells. The clinical trial testing this therapy has concluded and has led to another CIRM-funded trial by Forty-Seven, Inc.

Goal:

Safety. Dose range finding. Determination of maximum tolerated dose.